Lasa Supergenerics
Lasa Supergenerics (LASA) share price was ₹4.67 at the 26 Oct 2026 close; market capitalisation ₹23.40 Cr; sector Healthcare. The share price fell 56.0% over the year to 26 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue fell 93.9% year on year to ₹1.23 Cr and net profit was −₹3.58 Cr, against −₹21.12 Cr a year earlier (compared with Jun 2025). Promoters held 53.65% of Lasa Supergenerics in Mar 2026, unchanged from Dec 2025. Its Tapetide Score is 33/100 (Poor) as of 28 Oct 2026.
Key Fundamentals
Price-based figures as of 26 Oct 2026, 15:30 IST · EPS basis: Standalone · TTM
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,764.00 | 34.99 | 4,23,243 Cr | 5.06 | 0.91% | 13.79% | 17.94% | 61,848 Cr | 12,117 Cr | |
| ₹9,667.50 | 87.74 | 2,56,642 Cr | 15.31 | 0.32% | 15.32% | 18.96% | 11,682 Cr | 2,925 Cr | |
| ₹4,590.60 | 72.07 | 1,74,612 Cr | 9.50 | 0.82% | 12.16% | 9.06% | 17,058 Cr | 2,156 Cr | |
| ₹2,193.60 | 108.38 | 1,18,523 Cr | 22.36 | 0.09% | 16.38% | 19.67% | 7,323 Cr | 1,090 Cr | |
| ₹1,184.50 | 26.36 | 1,18,154 Cr | 4.36 | 0.09% | 16.99% | 19.24% | 28,515 Cr | 4,593 Cr | |
| ₹1,339.20 | 34.69 | 1,11,780 Cr | 2.88 | 0.61% | 10.87% | 13.94% | 34,247 Cr | 3,184 Cr | |
| ₹1,366.00 | 32.73 | 1,10,353 Cr | 3.12 | 0.96% | 11.21% | 14.88% | 28,589 Cr | 3,356 Cr | |
| Lasa Supergenerics (this company) | ₹4.67 | — | 23 Cr | — | 3.83% | 0.00% | 0.00% | 7 Cr | -17 Cr |
| Median 8 companies | ₹1,565.00 | 34.99 | 1,18,339 Cr | 5.06 | 0.72% | 12.98% | 16.41% | 22,787 Cr | 3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Data confidence 88/100
Category scores
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
1- Stock is trading at 0.52 times its book value
Weaknesses
3- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -34.0% over past five years.
- Company has a low return on equity of -9.95% over last 3 years.
Technical Indicators
Oscillators
Bullish
Overall
Bearish
Moving Averages
Bearish
Growth Rate
change over 1 year
change over 1 year
change over 1 year
change over 1 year Operating margin -113% · Jun 2026
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 30.56 | 24.3 | 26.66 | 22.82 | 30.84 | 39.39 | 33.08 | 39.14 | 20.01 | 3.06 | 2.2 | -0.13 | 1.23 |
| Expenses | 26.51 | 23.25 | 25.6 | 26.81 | 29.04 | 38.6 | 32.81 | 35.73 | 20.51 | 7.06 | 2.95 | 1.99 | 2.62 |
| Operating Profit | 4.05 | 1.05 | 1.06 | -3.99 | 1.8 | 0.79 | 0.27 | 3.41 | -0.5 | -4 | -0.75 | -2.12 | -1.39 |
| OPM % | 13.25% | 4.32% | 3.98% | -17.48% | 5.84% | 2.01% | 0.82% | 8.71% | -2.5% | -130.72% | -34.09% | — | -113.01% |
| Other Income | 0 | 0.08 | 0 | -8.76 | 0 | 1.95 | 8.91 | -21.52 | -20.44 | 0.01 | 0.02 | -0.42 | -0.38 |
| Interest | 0.37 | 0.56 | 0.44 | 0.56 | 0.87 | 1.24 | 0.47 | 0.11 | 0.03 | 0.12 | 0.11 | 0.13 | 0.14 |
| Depreciation | 2.65 | 2.68 | 2.68 | 2.66 | 2.79 | 2.81 | 2.8 | 3.9 | 1.57 | 1.57 | 1.57 | 1.31 | 1.57 |
| PBT | 1.03 | -2.11 | -2.06 | -15.97 | -1.86 | -1.31 | 5.91 | -22.12 | -22.54 | -5.68 | -2.41 | -3.98 | -3.48 |
| Tax % | 580.58% | -99.05% | -29.61% | -4.2% | 46.77% | 146.56% | 7.11% | -35.4% | -6.3% | 10.04% | 5.81% | 4.77% | 3.16% |
| Net Profit | -4.95 | -0.02 | -1.46 | -15.3 | -2.73 | -3.23 | 5.49 | -14.29 | -21.12 | -6.25 | -2.55 | -4.16 | -3.58 |
| EPS (₹) | -0.99 | 0 | -0.29 | -3.05 | -0.54 | -0.64 | 1.1 | -2.85 | -4.22 | -1.25 | -0.51 | -0.83 | -0.71 |
Profit & Loss
| Particulars | Mar 2016 1m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 199 | 244 | 170 | 167 | 201 | 137 | 130 | 104 | 142 | 25 | 6 |
| Expenses | 0 | 153 | 202 | 158 | 137 | 154 | 120 | 136 | 102 | 136 | 32 | 15 |
| Operating Profit | 0 | 46 | 41 | 11 | 30 | 47 | 16 | -6 | 2 | 6 | -7 | -8 |
| OPM % | — | 23% | 17% | 7% | 18% | 24% | 12% | -4.9% | 2.1% | 4.5% | -29% | -130% |
| Other Income | 0 | -24 | 3 | 0 | 0 | 0 | -8 | -18 | -9 | -11 | -21 | -1 |
| Interest | 0 | 12 | 11 | 8 | 8 | 2 | 0 | 4 | 2 | 3 | 0 | 0 |
| Depreciation | 0 | 8 | 18 | 19 | 17 | 16 | 15 | 13 | 11 | 12 | 6 | 6 |
| PBT | 0 | 2 | 15 | -16 | 5 | 30 | -6 | -42 | -19 | -19 | -35 | -16 |
| Tax % | — | -10% | 19% | -25% | 23% | 23% | -13% | -9% | 14% | -24% | -2% | — |
| Net Profit | 0 | 2 | 12 | -12 | 4 | 23 | -5 | -39 | -22 | -15 | -34 | -17 |
| EPS (₹) | — | — | 5.4 | -5.26 | 0.89 | 5.6 | -1.31 | -7.71 | -4.34 | -2.95 | -6.8 | -3.3 |
| Div. Payout % | — | 0% | 0% | 0% | 0% | 4% | -24% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.05 | 0.05 | 23 | 23 | 41 | 41 | 50 | 50 | 50 | 50 | 50 |
| Reserves | 0 | 75 | 94 | 82 | 101 | 118 | 108 | 68 | 47 | 34 | 0 |
| Borrowings | 0 | 116 | 107 | 85 | 48 | 19 | 20 | 22 | 22 | 2 | 10 |
| Other Liabilities | 0 | 37 | 63 | 69 | 42 | 29 | 31 | 24 | 32 | 16 | 7 |
| Total Liabilities | 0 | 228 | 287 | 258 | 232 | 208 | 209 | 164 | 151 | 102 | 67 |
| Fixed Assets | 0 | 119 | 170 | 162 | 152 | 143 | 137 | 119 | 110 | 68 | 55 |
| CWIP | 0 | 30 | 7 | 7 | 0 | 0 | 5 | 5 | 3 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 0 | 80 | 110 | 90 | 80 | 65 | 67 | 40 | 39 | 33 | 12 |
| Total Assets | 0 | 228 | 287 | 258 | 232 | 208 | 209 | 164 | 151 | 102 | 67 |
Cash Flow
| Particulars | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 0 | -3 | 40 | 41 | 14 | 41 | 9 | -17 | 2 | -3 | -8 |
| Investing | 0 | 0 | -44 | -7 | -2 | -4 | -3 | 11 | 0 | 8 | 0 |
| Financing | 0 | 0 | 4 | -33 | -10 | -36 | 0 | -4 | -2 | -6 | 7 |
| Net Cash Flow | 0 | -3 | 0 | 0 | 2 | 1 | 6 | -10 | 0 | 0 | 0 |
| Free Cash Flow | 0 | -5 | -6 | 29 | 13 | 35 | 12 | -12 | 0 | 5 | -7 |
| CFO/OP | — | -6 | 103 | 397 | 46 | 87 | 73 | 273 | 96 | -45 | 105 |
Ratios
| Particulars | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | — | 64 | 63 | 62 | 45 | 27 | 50 | 7 | 13 | 4 | 1 |
| Inventory Days | — | 93 | 90 | 90 | 101 | 56 | 46 | 48 | 92 | 84 | 28 |
| Days Payable | — | 71 | 102 | 170 | 130 | 41 | 68 | 32 | 68 | 35 | 33 |
| Cash Conversion Cycle | — | 87 | 51 | -18 | 16 | 42 | 28 | 22 | 37 | 53 | -4 |
| Working Capital Days | — | 15 | -1 | -52 | -13 | 35 | 12 | -17 | -44 | 37 | -102 |
| ROCE % | — | 42% | 13% | -4% | 7% | 17% | 1% | -12% | -6% | -1% | -18% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Lasa Supergenerics insights
65 extracted metrics + investor summaries across FY16–FY27.
Documents
Frequently Asked Questions about Lasa Supergenerics
What does Lasa Supergenerics Ltd do?
Where is Lasa Supergenerics Ltd (LASA) listed?
Which sector does Lasa Supergenerics Ltd belong to?
What is the market capitalisation of Lasa Supergenerics Ltd?
What is the 52-week high and low of Lasa Supergenerics Ltd?
Does Lasa Supergenerics Ltd pay dividends?
What is the Return on Equity (ROE) of Lasa Supergenerics Ltd?
Company Information
Incorporated in 2016, Lasa Supergenerics Ltd is in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/LASA.md for Lasa Supergenerics Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.